Tyra Biosciences, Inc. Common Stock (TYRA)
Tyra Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetically-defined cancers. Utilizing precision medicine approaches, Tyra aims to identify and develop novel treatments that address specific genetic alterations driving cancer growth. The company is engaged in research and development efforts to bring innovative cancer therapies to market.
Company News
BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.
Tyra Biosciences, a leading biotechnology company, has reached a new 52-week high of $21.67, reflecting its robust performance and investor confidence. The company has made progress in the development of its therapeutic candidate TYRA-300 for hypochondroplasia, with positive preclinical data presented at a research conference.
Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.8% on Friday. The Dow traded up 0.49% to 38,705.29 while the NASDAQ rose 1.81% to 15,639.81. The S&P 500 also rose, gaining, 1.20% to 4,965.03. Check This Out: Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday  Leading and Laggi...